Cue Biopharma, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Cue Biopharma, Inc. (CUE) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 4.16 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-14
- Cue Biopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 1.71M shares, a 52.00% increase year-over-year.
- Cue Biopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 1.13M shares, a 93.89% decline year-over-year.
- Cue Biopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 18.46M shares, a 13.71% increase year-over-year.
- Cue Biopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 16.23M shares, a 124.80% increase year-over-year.
- Cue Biopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 54.69M shares, a 110.44% increase from fiscal 2024.
- Cue Biopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 25.99M shares, a 30.02% increase from fiscal 2023.
- Cue Biopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 19.99M shares, a 14.48% increase from fiscal 2022.
- Cue Biopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 17.46M shares, a 164.37% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 4.16M shares 10-Q · filed 2026-08-14 | |||||||
| 2026-03-31 | 1.71M shares 10-Q · filed 2026-05-14 | |||||||
| 2025-12-31 | 54.69M shares 10-K · filed 2026-03-16 | |||||||
| 2025-09-30 | 35.18M shares 10-Q · filed 2025-11-12 | |||||||
| 2025-06-30 | 1.51M shares 10-Q · filed 2026-08-14 | 45.22M shares 10-Q · filed 2025-08-12 | ||||||
| 2025-03-31 | 1.13M shares 10-Q · filed 2026-05-14 | 33.83M shares 10-Q · filed 2025-05-12 | ||||||
| 2024-12-31 | 25.99M shares 10-K · filed 2026-03-16 | |||||||
| 2024-09-30 | 25.80M shares 10-Q · filed 2025-11-12 | |||||||
| 2024-06-30 | 18.65M shares 10-Q · filed 2025-08-12 | |||||||
| 2024-03-31 | 18.46M shares 10-Q · filed 2025-05-12 | |||||||
| 2023-12-31 | 19.99M shares 10-K · filed 2025-03-31 | 21.52M shares 10-K · filed 2024-03-28 | ||||||
| 2023-09-30 | 16.69M shares 10-Q · filed 2024-11-14 | 18.22M shares 10-Q · filed 2023-11-03 | ||||||
| 2023-06-30 | 16.29M shares 10-Q · filed 2024-08-14 | 17.82M shares 10-Q · filed 2023-08-08 | ||||||
| 2023-03-31 | 16.23M shares 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | 17.46M shares 10-K · filed 2024-03-28 | |||||||
| 2022-09-30 | 7.06M shares 10-Q · filed 2023-11-03 | |||||||
| 2022-06-30 | 7.10M shares 10-Q · filed 2023-08-08 | |||||||
| 2022-03-31 | 7.22M shares 10-Q · filed 2023-05-09 | |||||||
| 2021-12-31 | 6.60M shares 10-K · filed 2023-03-21 | |||||||
| 2021-09-30 | 6.52M shares 10-Q · filed 2022-11-14 | |||||||
| 2021-06-30 | 6.75M shares 10-Q · filed 2022-08-04 | |||||||
| 2021-03-31 | 6.80M shares 10-Q · filed 2022-05-10 | |||||||
| 2020-12-31 | 6.12M shares 10-K · filed 2022-03-16 | |||||||
| 2020-09-30 | 6.32M shares 10-Q · filed 2021-11-09 | |||||||
| 2020-06-30 | 6.34M shares 10-Q · filed 2021-08-09 | |||||||
| 2020-03-31 | 6.95M shares 10-Q · filed 2021-05-10 | |||||||
| 2019-12-31 | 6.05M shares 10-K · filed 2021-03-09 | |||||||
| 2019-09-30 | 5.88M shares 10-Q · filed 2020-11-09 | |||||||
| 2019-06-30 | 6.06M shares 10-Q · filed 2020-08-07 | |||||||
| 2019-03-31 | 6.47M shares 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | 5.79M shares 10-K · filed 2020-03-12 | |||||||
| 2018-09-30 | 5.68M shares 10-Q · filed 2019-11-07 | 5.68B shares 10-Q · filed 2018-11-13 | ||||||
| 2018-06-30 | 4.64M shares 10-Q · filed 2019-08-08 | 4.64B shares 10-Q · filed 2018-08-13 | ||||||
| 2018-03-31 | 4.01M shares 10-Q · filed 2019-05-08 | 4.01M shares 10-Q · filed 2018-05-14 | ||||||
| 2017-12-31 | 3.98M shares 10-K · filed 2019-03-14 | |||||||
| 2017-09-30 | 2.74B shares 10-Q · filed 2018-11-13 | |||||||
| 2017-06-30 | 2.74B shares 10-Q · filed 2018-08-13 | |||||||
| 2017-03-31 | 2.21M shares 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |